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Temporal and Seasonal Changes of Genetic Polymorphisms Associated
with Altered Drug Susceptibility to Chloroquine, Lumefantrine, and
Quinine in Guinea-Bissau between 2003 and 2012
Irina Tatiana Jovel,a,b Poul-Erik Kofoed,c,d Lars Rombo,e Amabelia Rodrigues,c Johan Ursinga,c,f
Malaria Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Swedena; Departamento de Parasitología, Escuela de
Microbiología, Facultad de Ciencias, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Hondurasb; Projecto de Saúde de Bandim, Indepth Network,
Bissau, Guinea-Bissauc; Department of Paediatrics, Kolding Hospital, Kolding, Denmarkd; Centre for Clinical Research, Sörmland County Council, Uppsala, Swedene;
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Swedenf
In 2008, artemether-lumefantrine was introduced in Guinea-Bissau, West Africa, but quinine has also been commonly pre-
scribed for the treatment of uncomplicated Plasmodium falciparummalaria. An efficacious high-dose chloroquine treatment
regimen was used previously. Temporal and seasonal changes of genetic polymorphisms associated with altered drug suscepti-
bility to chloroquine, lumefantrine, and quinine have been described. P. falciparum chloroquine resistance transporter (pfcrt)
K76T, pfmdr1 gene copy numbers, pfmdr1 polymorphisms N86Y and Y184F, and pfmdr1 sequences 1034 to 1246 were deter-
mined using PCR-based methods. Blood samples came from virtually all (n 1,806) children<15 years of age who had uncom-
plicated P. falciparummonoinfection and presented at a health center in suburban Bissau (from 2003 to 2012). The pfcrt K76T
and pfmdr1N86Y frequencies were stable, and seasonal changes were not seen from 2003 to 2007. Since 2007, the mean annual
frequencies increased (P< 0.001) for pfcrt 76T (24% to 57%), pfmdr1N86 (72% to 83%), and pfcrt 76 pfmdr1 86 TN (10% to
27%), and pfcrt 76T accumulated during the high transmission season (P 0.001). The pfmdr1 86 184 NF frequency increased
from 39% to 66% (from 2003 to 2011; P 0.004). One sample had two pfmdr1 gene copies. pfcrt 76T was associated with a
lower parasite density (P< 0.001). Following the discontinuation of an effective chloroquine regimen, probably highly
artemether-lumefantrine-susceptible P. falciparum (with pfcrt 76T) accumulated, possibly due to suboptimal use of quinine
and despite a fitness cost linked to pfcrt 76T. (The studies reported here were registered at ClinicalTrials.gov under registration
no. NCT00137514 [PSB-2001-chl-amo], NCT00137566 [PSB-2004-paracetamol], NCT00426439 [PSB-2006-coartem],
NCT01157689 [AL-eff 2010], and NCT01704508 [Eurartesim 2012].)
Plasmodium falciparum malaria is a major cause of morbidityand mortality in sub-Saharan Africa (1). Due to the develop-
ment and spread of P. falciparum resistance to commonly avail-
able monotherapies, the World Health Organization recom-
mends the use of artemisinin-based combination therapy (ACT)
for the treatment of uncomplicated malaria (2). Therefore, Guin-
ea-Bissau, inWest Africa, replaced an apparently efficacious high-
dose chloroquine (CQ) regimen with an equally efficacious arte-
mether-lumefantrine (AL) regimen in 2008 (3). Quinine was and
is recommended for the treatment of severe malaria in Guinea-
Bissau. However, in clinical practice, it is also commonly used for
nonsevere malaria (4). The P. falciparum incidence and preva-
lence decreased to all-time lows between 2003 and 2007, prior to
the change in treatment policy, and then resurged in an epidemic
fashion, particularly in older children between 2008 and 2011,
following the introduction of AL (5).
CQ resistance and reduced tolerance to lumefantrine have
been linked to single nucleotide polymorphisms (SNPs) in the P.
falciparum CQ resistance transporter gene (pfcrt) and multidrug
resistance gene 1 (pfmdr1) (6–10). pfcrt 76T is essential for resis-
tance to the standard dose of CQ, and additional SNPs in pfcrt and
pfmdr1 86Y appear to compensate for fitness loss and tomodulate
CQ susceptibility (11). In Guinea-Bissau, CQ resistance was
linked to the pfcrt haplotype 72–76 CVIET  271E  326S,
whereas the haplotype 72–76 CVMNK  Q271  N326 was
linked to CQ sensitivity (12, 13). pfcrt K76 and pfmdr1 N86 are
selected for after treatment with AL and are linked to reduced
lumefantrine susceptibility (7–9, 14). The pfmdr1 86  184 
1246 NFD haplotype has been selected for by AL (7, 15, 16). Fur-
thermore, an increased pfmdr1 copy number has been linked to
reduced susceptibility to artemisinin derivatives, lumefantrine,
piperaquine, and mefloquine and to artesunate plus mefloquine
treatment failure (17–20). In addition to these well-characterized re-
sistance-associated SNPs, pfmdr1 polymorphisms N86Y, S1034C,
N1042D, andD1246Y have been suggested tomodulate levels of CQ
and quinine resistance (21, 22).
P. falciparum in Guinea-Bissau recently had to adapt to chang-
ing drug pressure and changing epidemiology (5). These factors
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are likely to affect the prevalence of P. falciparum through genetic
polymorphisms associated with reduced drug susceptibility, espe-
cially as CQ resistance, at least, has been associated with a cost to
parasite fitness (23). As part of the clinical trials conducted within
the Bandim Health and Demographic Surveillance Site (HDSS),
blood has been collected for genotyping. The primary aim of this
study was to determine the temporal and seasonal frequencies of
genotypes associated with reduced susceptibilities to CQ, AL, and
quinine between 2003 and 2012.
MATERIALS AND METHODS
Study area and population. The studies were conducted at the Bandim
HDSS in suburban Bissau, the capital of Guinea-Bissau. The Bandim
Health Centre is located centrally within the HDSS, and nurses see pedi-
atric patients in the mornings, afternoons, and weekends. There is a lab-
oratory manned by trained technicians.
Data collection. This report is based on five clinical trials. Three trials
conducted between 2001 and 2008 have been published (3, 12, 24, 25).
One trial conducted between 2010 and 2012 has been completed, and
analyses are ongoing. Another ongoing trial started in November 2012.
Thus, part of the data collected between 2003 and 2008 has been pub-
lished; however, the data form a necessary background for this paper with
a different aim and are therefore included (3, 12, 24–27). No clinical trial
was conducted in 2009, so there are no data from that year. The inclusion
criteria used in all the studies were an age of15 years, residence within
the HDSS, fever or history of fever, monoinfection with P. falciparum, a
parasite density of800/l, and no signs or symptoms of severe malaria.
Malaria diagnoses.Thick and thin Giemsa-stained smears weremade
from blood obtained by finger-pricks to identify species and quantify
asexual parasite density (per 200 white blood cells) using1,000 magni-
fication and a sunlit microscope. A slide was considered negative after
examination of 100 high-power fields. Rapid diagnostic tests have been
available since 2010, but all stains from the children with possible malaria
were also screened using microscopy.
Treatment.Although the official treatment dosewas 25mg/kg of body
weight of CQ over 3 days, an efficacious high-dose CQ treatment regimen
was used until June 2008, when AL was introduced as part of national
policy for the treatment of uncomplicated malaria (3, 13, 28). The origin
of the high-dose treatment regimen is not certain but was probably a
misinterpretation of the 25-mg/kg dose over 3 days as 25 mg/kg per day
for 3 days. Quinine remained the drug of choice for severe malaria
throughout this time. CQ was also commonly used for the home treat-
ment of a fever presumed to be caused by malaria, at least until the intro-
duction of AL. The introduction of AL was widely announced by the
media, and people were told to stop using CQ.
The drugs used as part of the studieswereCQor amodiaquine (2001 to
2004), CQ (2004 to 2006), CQ or AL (2006 to 2008), and dihydroartemis-
inin-piperaquine or AL (November 2012 to present). As part of an effec-
tiveness study (2010 to 2012), antimalarial drug use wasmonitored in 799
children with uncomplicated malaria; AL was prescribed to 47% of them,
quinine to 43%, quinine-AL to 9%, and CQ to 1%. Children with recur-
rent parasitemia during the study follow-up period were re-treated with
sulfadoxine-pyrimethamine, CQ (50 mg/kg), or AL, depending on the
study.
Sample collection, storage, and DNA extraction. After inclusion on
day 0, blood was put onto filter papers (Whatman 3MM), dried, and
stored in individual plastic bags until DNA extraction was performed.
Approximately 25l of blood was cut from the filter papers and extracted
on an Applied Biosystems Prism 6100 Nucleic Acid PrepStation for stud-
ies conducted between 2003 and 2011. The extraction was performed
according to the manufacturer’s protocol for the isolation of DNA from
whole blood, with minor modifications. Since mid-2011, DNA was ex-
tracted using a Chelex-based method. The extracted DNA was stored at
20°C until use.
PCR analyses. Previously described multiplex restriction fragment
length polymorphism PCR methods were used to detect pfcrt K76T and
pfmdr1 N86Y and Y184F SNPs (6, 29, 30).
Pfmdr1 codons 1034 to 1246 were ascertained by PCR amplification,
followed by sequencing, using previously described PCR protocols (7).
The Sequencher software version 4.6 (Gene Codes Corporation, Ann Ar-
bor, MI) was used for sequencing analysis. The sequences of the P. falcip-
arum 3D7 clone obtained from theNCBI database were used as references
for pfmdr1 (accession no. XM_001351751.1). The PCR and restriction
products were resolved on 2% agarose gels (Amresco, Solon, OH). All the
gels were stained with a nucleic acid gel stain (ethidium bromide or
GelRed; Biotium, Inc., Hayward, CA, USA) and visualized under UV
transillumination (Gel Doc; Bio-Rad, Hercules, CA, USA). The PCR
products were purified and sequenced commercially (Macrogen, Inc.,
Seoul, South Korea).
Statistics. SNP frequency was calculated as the number of samples
with a certain allele. Thus, mixed infections were counted twice. Haplo-
type frequencywas calculated after excludingmixed infections. The yearly
and seasonal changes of allele and haplotype frequencies were estimated
using logistic regression with bootstrapping (100 repeats), with year or
month as the continuous covariate and the earliest time point as the base-
line. For the calculation of seasonal changes, February was the earliest
time point, as the high-transmission season ends in January. Parasite den-
sities and ages were estimated and compared using quantile regression
with bootstrapping (100 repeats). The linkage disequilibrium was calcu-
lated as a correlation coefficient (r) between pairs of loci after excluding
mixed infections. A correlation coefficient of 1 indicated absolute corre-
lation, 0 indicated no correlation, and1 indicated total negative corre-
lation.
Ethics statement. Each patient was included in the respective clin-
ical studies after informed consent was received from his or her care-
taker. Ethical approval was granted by the ethical review board in
Bissau, Guinea-Bissau (Parecet NCP/N19/2006, 019/DHE/2004, and
064/DGSP/2006), the regional ethics committee in Stockholm, Swe-
den (2005/111-31/1, 2006/1151-31/1, and 2011/832-32/2), and the
central scientific ethics committee in Denmark (624-01-0042). All
these studies were also registered at ClinicalTrials.gov under registra-
tion no. NCT00137514 (PSB-2001-chl-amo), NCT00137566 (PSB-
2004-paracetamol),NCT00426439(PSB-2006-coartem),NCT01157689(AL-eff
2010), andNCT01704508 (Eurartesim2012).
RESULTS
A total of 1,806 children aged less than 15 years with uncompli-
cated P. falciparum monoinfection were included from 2003 to
2012. The basic demographic characteristics are shown in Table 1.
TABLE 1 Baseline characteristics of children who had P. falciparum
monoinfection and attended the Bandim Health Centre between 2003
and 2012
Yr
No. of
children Sex ratio (M:F)a Age (95% CI)b
2003 342 160:182 5.7 (5.1–6.2)
2004 179 96:83 5 (3.8–6.2)
2005 173 85:88 5.4 (4.9–5.9)
2006 89 47:42 5.0 (4–5.9)
2007 40 22:18 5.1 (3.9–6.2)
2008 141 52:37 6.5 (5.7–7.4)
2010 345 180:165 8.8 (8–9.5)
2011 360 205:154 9.0 (8.3–9.7)
2012 137 74:63 10.0 (9.3–10.7)
a Sex was not recorded at the end of 2008, and data were missing for one patient in
2011.
b CI, confidence interval.
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There were 921 male and 832 female children. Sex was not re-
corded at the end of 2008, which accounts for the discrepancy in
the total number of children. Prior to 2008, malaria cases were
detected throughout the year, with peaks at the beginning (June)
and end (October to November) of the rainy season. Between
2008 and 2012, malaria became epidemic, with a single high peak
in November. Between 2003 and 2012, the annual median age
increased from 5 years 8 months to 10 years (P 0.001).
pfcrt K76T allele frequencies over time. Figure 1, top, and
Table 2 show the pfcrt K76T frequencies over time, the number of
children with malaria each year, and the recommended 1st-line
antimalarial drugs used. The pfcrt K76 and 76T frequencies were
stable at80% and24%, respectively, between 2003 and 2007.
After 2007, the pfcrtK76 frequency decreased (P 0.001), and the
mean frequency between 2008 and 2012 was 67% (598/896). The
pfcrt 76T frequency increased significantly (P  0.001) between
2007 and 2012. More specifically, the pfcrt 76T frequency gradu-
ally increased to 57% between 2007 and 2011 and then appeared
to decrease to 34% in 2012.
pfmdr1N86Y allele frequencies over time. The pfmdr1N86Y
allele frequencies did not change significantly before 2007. The
pfmdr1 N86 frequency increased significantly (63% to 83%, P 
0.001) and the pfmdr1 86Y frequency decreased significantly (48%
to 34%, P  0.001) between 2007 and 2012, as shown in Fig. 1,
bottom, and Table 2.
Other pfmdr1 SNPs over time. The pfmdr1 Y184F allele fre-
quencies did not change significantly over time, as shown in Table
2. The SND haplotype was found in pfmdr1 1034, 1042, and 1246
in 137 of 138 samples between 2003 and 2004 and in 315 of 316 in
2011. During the same years, the SNY haplotype was found in 1 of
138 and 1 of 316 samples, respectively.
Sequencing of all samples collected in 2011 identified the non-
synonymous SNPs 1082tcc¡gcc (2/316), 1199aat¡aag (5/316),
and 1241gat¡aat (2/316) and the synonymous SNPs 1069act¡
acg (40/317), 1158aca¡acg (1/317), and 1243aac¡aat (1/316).
The pfcrt and pfmdr1 haplotypes for the novel SNPs listed above
are shown in Table S1 in the supplemental material. The pfmdr1
SNP 1069acg was found together with pfcrt K76 in 27/146 (18%)
samples and with pfcrt 76T in 8/104 (8%) samples (P  0.015)
after the exclusion of mixed infections. No other significant asso-
ciations were found.
pfmdr1 amplifications. One gene copy was found in 1,635
samples, and 1.5 copies were found in two samples. One sample
had two copies, as shown in Table 2.
Haplotype frequencies.The pfcrtK76T and pfmdr1N86Yhap-
lotype frequencies are shown in Table 3 and Fig. 2. The numbers
are lower than the individual SNP frequencies, as mixed infections
FIG 1 pfcrt K76T and pfmdr1 N86Y allele frequencies in children aged less
than 15 years who attended the BandimHealthCentre between 2003 and 2012.
LLIN,mass distribution of long-lasting insecticide-treated bed nets inNovem-
ber 2011.
TABLE 2 pfcrt K76T frequencies, pfmdr1 N86Y frequencies, and pfmdr1 gene copy numbers between 2003 and 2012 among children diagnosed with
P. falciparum malaria at the Bandim Health Centre
Yr
Frequency (% [no. with a specific allele/total no. of successfully amplified samples]) for:
No. of samples with
pfmdr1 copy no. of:pfcrt pfmdr1
K76 76T N86 86Y F184 184Y 1 1.5 2
2003 79 (253/318) 24 (75/318) 72 (227/317) 47 (149/317) 79 (251/317) 37 (118/317) 311
2004 79 (119/151) 25 (37/151) 70 (108/155) 43 (66/155) 152
2005 80 (136/169) 23 (39/169) 79 (134/170) 36 (61/170) 173
2006 84 (74/88) 23 (20/88) 80 (70/88) 42 (37/88) 88
2007a 80 (32/40) 25 (10/40) 63 (25/40) 48 (19/40) 39
2008 71 (95/134) 31 (42/134) 71 (96/135) 36 (49/135) 138 1
2010 65 (193/296) 48 (141/296) 78 (232/297) 30 (89/297) 76 (218/288) 42 (121/288) 271 1 1
2011 65 (224/345) 57 (195/345) 77 (249/322) 29 (93/322) 74 (245/332) 41 (136/332) 337
2012 71 (86/121) 34 (41/121) 83 (105/126) 34 (43/126) 79 (73/92) 46 (42/92) 126
a pfcrt K76T and pfmdr1 N86Y frequencies did not change significantly before 2007. pfcrt K76 decreased (P 0.001) and pfcrt 76T increased (P 0.001) after 2007. pfmdr1 N86
increased and pfmdr1 86Y decreased significantly (both P 0.001) between 2007 and 2012. pfmdr1 Y184F did not change significantly.
Jovel et al.
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were excluded. pfcrt 76 pfmdr1 86 KN (P 0.002) and KY (P
0.001) decreased significantly, whereas TY remained stable at10%
between 2003 and 2012. TheTN frequencywas10%between 2003
and 2007 but then increased to 27% by 2012 (P 0.001).
The pfmdr1 86 184NF frequency increased significantly over
time (P  0.004), while that of YF decreased significantly (P 
0.001). NY and YY frequencies did not change significantly.
The triple haplotypes pfcrt 76 pfmdr1 86 pfmdr1 184 were
determined in 219, 200, 191, and 42 samples in 2003, 2010, 2011,
and 2012, respectively. During these years, the KNF frequencies
were 32%, 37%, 25%, and 45%, respectively, and did not change
significantly (P 0.8). KYF decreased from 24% to 7%, 11%, and
7% from 2003 to 2010, 2011, and 2012, respectively (P 0.001).
From 2003 to 2010, 2011, and 2012, TNF increased from 7% to
17%, 17%, and 21%, respectively (P 0.002), and TNY increased
from 3% to 10%, 13%, and 7%, respectively (P 0.001).
Linkage disequilibrium. Correlation coefficients for pfcrt 76
and pfmdr1 86 decreased for KN and TY and increased from neg-
ative values (indicating negative correlation) for KY and TN over
time.When the datawere pooled, the correlation coefficients were
0.26 (2003 to 2007) and 0.12 (2008 to 2012) for KN and TY and
0.26 and0.12 for KY and TN. No changes were seen with pfcrt
K76T and pfmdr1Y184F. The pfmdr1 86 pfmdr1 184NY and YF
correlation coefficients decreased from 0.34 in 2003 to 0.15 in
2010 to 2012, while NF and YY increased from 0.34 to 0.15
over the same time period.
Seasonal trends. There were no seasonal variations between
2003 and 2007. Between 2008 and 2012, pfcrt 76T increased from
an average of 37% (50/136) during the low-transmission period
(February to July) to 55% (69/126) at the end of the high-trans-
mission period (December; P  0.03). In parallel, pfcrt 76K pos-
sibly decreased from an average of 74% (100/136) during the low-
transmission period (February to July) to 59% (74/126) in
December (P  0.05), as shown in Fig. 3, top. The pfcrt 76 
pfmdr1 86 TN frequency increased significantly from 18% (17/97,
February to July) to 31% in December (P  0.045) (Fig. 3, bot-
tom). The pfmdr1N86Y, pfcrtK76T pfmdr1 F184Y, and pfmdr1
N86Y pfmdr1 F184Y frequencies showed no consistent seasonal
variations.
Parasite densities. The median parasite densities (P. falcipa-
rum parasites/l) with pfcrt K76T and pfmdr1 N86Y alleles and
haplotypes are shown in Table 4. pfcrt K76 was associated with a
significantly higher day 0 parasite density than pfcrt 76T (P 
TABLE 3 Pfcrt K76T and pfmdr1 N86Y haplotype frequencies between 2003 and 2012 among children diagnosed with P. falciparum malaria at the
Bandim Health Centre
Yr
pfcrt K76T pfmdr1 N86Y haplotype pfmdr1 N86Y pfmdr1 F184Y haplotype
Total no. of
samples
Frequency (% [no. of samples with haplotype]) for:
Total no. of
samples
Frequency (% [no. of samples with haplotype])
for:
KNa KYa TNb TY NFc NY YFd YY
2003 254 56 (142) 23 (59) 9 (24) 11 (29) 223 39 (87) 22 (49) 37 (82) 2 (5)
2004 129 56 (72) 21 (27) 9 (11) 15 (19)
2005 139 65 (91) 14 (20) 10 (14) 10 (14)
2006 65 63 (41) 15 (10) 11 (7) 11 (7)
2007 36 47 (17) 31 (11) 11 (4) 11 (4)
2008 121 46 (56) 23 (28) 22 (27) 8 (10)
2010 263 50 (132) 10 (26) 26 (68) 14 (37) 221 52 (116) 25 (55) 19 (41) 4 (9)
2011 263 46 (122) 12 (31) 29 (75) 13 (35) 246 46 (114) 27 (66) 22 (54) 5 (12)
2012 89 54 (48) 10 (9) 27 (24) 9 (8) 50 66 (33) 24 (12) 10 (5) 0 (0)
a KN (P 0.002) and KY (P 0.001) frequencies decreased over time.
b TN frequency increased between 2007 and 2012 (P 0.001).
c NF frequency increased (P 0.004).
d YF frequency decreased over time (P 0.001).
FIG 2 Frequencies of pfcrtK76 and pfcrt 76 pfmdr1 86 KN or KY haplotypes
(A) and pfcrt 76T and pfcrt 76 pfmdr1 86 TN or TY haplotypes (B) between
2003 and 2012.
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0.005). The parasite density was nonsignificantly higher with
pfmdr1 N86 than with pfmdr1 Y86 (P  0.16). There were no
differences between the pfmdr1Y184F alleles. Themedian parasite
densities were significantly higher with pfcrt 76  pfmdr1 86 KN
(P 0.008) and KY (P 0.004) than with TY, but there were no
significant differences between KN or KY and TN.
DISCUSSION
We present here unique data on resistance-associated genetic
polymorphisms collected from virtually all children aged 15
years with uncomplicated malaria and who attended a Guinea-
Bissau health center each year in a 9-year period. During this pe-
riod, P. falciparum epidemiology changed dramatically, the treat-
ment policy changed from an efficacious high-dose CQ regimen
to ACT in 2008, and long-lasting insecticide-treated bed nets were
mass distributed in 2011 (5).
Perhaps the most striking finding was the decreasing pfcrt K76
frequency and increasing pfcrt 76T frequency following the intro-
duction of AL in 2008. pfcrtK76 has been associated with reduced
susceptibility to lumefantrine and has been selected for after treat-
ment with AL (3, 8, 14). Furthermore, pfcrt 76T has been associ-
ated with a fitness cost, and it rapidly disappeared in other settings
when CQ use was discontinued (23, 31, 32). Therefore, the in-
creased pfcrt 76T anddecreased pfcrtK76 frequencies contradicted
expectations.
Although AL was the recommended drug, quinine was pre-
scribed to 43% of the children diagnosed with P. falciparum ma-
laria between 2010 and 2012 (our unpublished data). Further-
more, the preliminary data indicate that treatment with quinine
selected for pfcrt 76T among recrudescing P. falciparum. Other
studies have indicated that pfcrt is involved in the transport of
quinine and that SNPs in pfcrt, including 76T, decrease P. falcip-
arum susceptibility to quinine (22, 33–35). Thus, it seems highly
probable that the increased pfcrt 76T frequency was due to the
increased use of quinine. The accumulation of pfcrt 76Tduring the
high-transmission season (Fig. 3), indicating that pfcrt 76T con-
ferred a selective advantage as drug pressure increased, further
supports this. Interestingly, this was not seen when high-dose CQ
was used, indicating that 76T provided a greater selective advan-
tage when quinine was used than when high-dose CQ was used.
An alternative explanation for the accumulation of pfcrt 76T is
selective pressure by AL. However, a study completed in 2008
indicated that AL selected for pfcrt K76 in Bissau as it does else-
where, suggesting that selective pressure is unlikely (3, 8). Contin-
ued CQ use might also select for pfcrt 76T. However, based on
prescription data collected from 2010 to 2012 and informal ques-
tioning, CQ is hardly used anymore. Furthermore, if CQ was the
driving force, a novel lower and less efficacious CQ dose than that
routinely used in the past would have had to have been used. The
increased pfcrt 76T frequency might also be the result of selection
after the 2007 bottleneck event (when malaria drastically de-
creased) due to a selective advantage in older children or better
inherent fitness. For example, older childrenmay bemore likely to
self-medicatewithCQat homeprior to seeking care at the Bandim
Health Centre, or pfcrt 76Tmay be accompanied by other fitness-
restoring genetic changes not examined in this study (36). How-
ever, SNP frequencies did not vary with age, and proxies for fit-
ness, such as a lower parasite density and lower pfcrt 76T
frequency during the low-transmission period, suggest that pfcrt
76T was associated with a fitness cost, not a benefit.
Further analysis revealed that pfcrt 76  pfmdr1 86 TN in-
creased between 2007 and 2012. The increased TN haplotype
might be due to direct selection by quinine. However, decreased
quinine susceptibility has more often been linked with the TY
haplotype (22, 35). The discrepancy may be due to the probable
multigenic basis of quinine resistance (22, 37). Alternatively, the
TABLE 4 P. falciparum parasite densities correlated to pfcrt K76T and
pfmdr1 N86Y alleles and haplotypes
SNPa or pfcrt 76
pfmdr1 86 haplotype No.
Median density
(P. falciparum
parasites/l)
95% confidence
interval P value
pfcrt K76 1,062 18,000 16,773–19,227 0.005b
pfcrt 76T 450 15,120 13,805–16,434
pfmdr1 N86 1,041 17,600 15,778–19,421 0.16c
pfmdr1 86Y 205 15,960 14,325–17,594
KN 689 18,000 16,432–19,568
KY 217 18,400 16,484–20,316
TN 240 15,840 12,917–18,762
TY 158 14,640 13,093–16,187 0.01d
a SNP, single nucleotide polymorphism.
b pfcrt K76 was associated with a higher parasite density than pfcrt 76T.
c Parasite density did not differ significantly between pfmdr1 N86Y alleles.
d The pfcrt 76T pfmdr1 86Y haplotype was associated with significantly lower parasite
densities than the pfcrt K76 pfmdr1 N86 (P 0.008) or pfcrt K76 pfmdr1 86Y (P
0.004) haplotypes.
FIG 3 Monthly pfcrtK76T allele, pfcrt 76T pfmdr1N86 haplotype, and pfcrt
76T pfmdr1 86Y haplotype frequencies between 2008 and 2012.
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TN haplotype is inherently fitter than TY, at least in Guinea-Bis-
sau. The significantly lower parasite density found with TY (but
not with TN) compared to that with KNorKYmight support this,
assuming that the day 0 parasite density is a proxy for inherent
parasite fitness.
Reduced susceptibility to lumefantrine and recurring parasites
after treatment with AL have been linked to pfmdr1 N86, the
pfmdr1 86 184 1246 NFD haplotype, and pfmdr1 amplifica-
tions in addition to pfcrtK76 (3, 7–9, 14–16, 38). Increased pfmdr1
N86 and pfmdr1 86 184NF haplotype frequencies following the
introduction of AL are in line with these previous observations. As
pfmdr1 D1246 was fixed at 100% frequency in our study area,
the selection of pfmdr1 86 184 NF actually represented a selec-
tion of the pfmdr1NFDhaplotype that has been linked to a 15-fold
higher in vivo AL tolerance (7). As quinine probably selected the
pfcrt 76  pfmdr1 TN haplotype and both the pfcrt 76  pfmdr1
86 184 TNF and TNY haplotypes increased, it seems likely that
neither pfmdr1 Y184F allele conferred a selective advantage
against quinine. The increased NF frequency was therefore more
likely driven by AL than by quinine.
Despite the detection of the first sample with two pfmdr1 gene
copies in 2008, the frequency did not subsequently increase, sug-
gesting that the increased copy number did not provide P. falcip-
arum with a great selective advantage in Guinea-Bissau. Alterna-
tively, finding so few samples with increased copy numbers might
well be within the margin of error when doing PCRs, suggesting
that no samples exist in Bissau. Either way, P. falciparum with
multiple pfmdr1 copies has not becomewidespread inBissau, con-
trary to the situation in Ghana, where relatively high frequencies
were recently reported (38).
A concern when using AL as a first-line antimalarial is that
reduced susceptibilities to artemether and lumefantrine have been
linked to some of the same genetic polymorphisms (17–19, 21).
The use of multiple first-line therapies that select for opposing
genetic polymorphismsmight therefore be of value. Furthermore,
modeling has suggested that the use ofmultiple first-line therapies
may prolong the total lifetime of the first-line drugs in use over
that achieved with sequential use (39). Although by no means
solid evidence, our findings of an increased pfcrt 76T frequency
that probably reflects the increased prevalence of highly AL-sus-
ceptible P. falciparum (compared to that of 76K) when AL and
quinine are used concurrently support that hypothesis. Beyond
the use of multiple first-line therapies, this balancing of opposing
forces is of relevance for the design of antimalarial therapies that
aim to decrease the risk of drug resistance. However, it is impor-
tant to note that our results were probably a consequence of the
poor effectiveness of quinine as used in Guinea-Bissau.
The low and stable frequencies of pfcrt 76T when CQ was used
(2003 to 2007) were probably due to the routine use of approxi-
mately three times the standard dose of CQ that cured the major-
ity of children infected with pfcrt 76T-carrying P. falciparum (3,
12, 13, 28). Thus, pfcrt 76Tprovided little advantage over pfcrtK76
and did not accumulate, as discussed in detail in a previous paper
(13). Our present results showing that the pfcrt 76T frequency
increased when the use of high-dose CQ was stopped support the
previous data and are of particular interest whenever the reintro-
duction of CQ is considered (32). If standard-dose CQ is reintro-
duced, it is likely that the pfcrt 76T frequency will rapidly increase,
whereas the introduction of a higher efficacious dose may avoid
this.
A further noteworthy observation is that the pfcrt K76T alleles
did not vary over the seasons prior to 2008. This was probably due
to the relatively low frequency of pfcrt 76T, the	95% efficacy of
high-dose CQ, and the lack of a selective advantage of 76T when
CQ that hindered its accumulation during the peakmalaria trans-
mission season was used. The seasonality seen since 2008 is prob-
ably largely an effect of the poor effectiveness of quinine in routine
practice. In Bissau, quinine is typically given for 3 days (4), and
this was a common dosage from 2010 to 2012 (our unpublished
data). In a previous efficacy study in Bissau, 33% of children had
recurrent parasitemia by day 28 when treated with 15 mg/kg of
quinine twice daily for 3 days (4). It is thus probable that treatment
failure following the use of quinine resulted in the accumulation
of pfcrt 76T during the high-transmission season.
The decreased pfcrt 76T frequencies between 2011 and 2012
occurred concurrently with a halving of the P. falciparum inci-
dence that probably represented a major selective event due to
mass distribution of long-lasting insecticide-treated bed nets at
the end of 2011. In addition, an efficacy study started inNovember
2012 possibly reduced quinine use. The decreased pfcrt 76T fre-
quencies might thus reflect decreased quinine use partly due to a
new study starting but also because of fewer occurrences of ma-
laria. As pfcrt 76T accumulated during the transmission season,
the smaller epidemic seen in 2012 probably resulted in less 76T
accumulation and therefore a lower frequency compared to those
in the larger epidemics in 2010 and 2011.
We also found a number of novel synonymous and nonsyn-
onymous SNPs in pfmdr1. This is in line with previous studies
indicating that pfmdr1 can be quite variable (40, 41). None of the
SNPs found were common, suggesting that the SNPs did not pro-
vide a major selective benefit, at least not yet. The synonymous
pfmdr1 1069acg SNP was described previously for a single sample
fromMadagascar (41) and for 10% of samples collected in Liberia
in 1978 (our unpublished data). Themore commonoccurrence of
pfmdr1 1069acg with pfcrt 76K than with 76T in this study may
suggest greater genetic variability in clones with pfcrt 76K but
should be interpreted with considerable caution.
To conclude, we report here the frequencies of major genetic
polymorphisms linked to reducedAL andCQ susceptibilities over
a 9-year period in Guinea-Bissau. Despite being linked to a prob-
able fitness cost, the pfcrt 76T frequencies increased when AL of-
ficially replaced CQ as the first-line therapy. This was probably
largely driven by quinine that was used as commonly as AL was.
Most probably, highly artemether-lumefantrine-susceptible P.
falciparum therefore accumulated, possibly supporting the use of
multiple first-line therapies. The pfmdr1 86  184 NF and prob-
ablyD1246 haplotypes also increased, possibly driven byAL. Prior
to the changed treatment policy, the pfcrt 76T frequencywas stable
at24%when an efficacious high dose of CQwas used; this find-
ing will have implications whenever the reintroduction of CQ is
considered.
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